Diginex Misses Its Own Deadline, Leaving a $1.5 Billion Deal in Limbo and a Stock at Risk

Diginex shares fall 7% to $0.90 after missing Resulticks acquisition deadline; Nasdaq delisting risk looms as stock trades near 52-week low.

The clock ran out on Diginex’s proposed takeover of Resulticks on June 12, and investors responded by driving the stock further below the $1 mark. Shares closed at $0.90 Friday, a daily loss of nearly 7%, bringing the 30-day decline to 25%. At $0.88, the 52-week low is now within striking distance. The company had already pushed the original closing date back from May 29, but the extra two weeks weren’t enough to satisfy outstanding conditions.

The disparity between target and buyer is staggering. Resulticks carries a $1.5 billion price tag, generating roughly $150 million in annual revenue with EBITDA between $46 million and $50 million. Diginex, by contrast, trades with a market capitalization of about €26 million—roughly $28 million. Completing the deal would transform the RegTech specialist into an integrated data, ESG, and customer-intelligence platform. But the arithmetic leaves little room for error in financing.

Management hasn’t been idle. On June 10, founder Miles Pelham—who has personally poured more than $25 million into the company—appointed Carole Zibi as chief marketing officer to unify the business lines into a single global brand. Earlier in the month, Diginex launched “Risk-to-Remedy,” a supply-chain due diligence solution targeting a market that could hit nearly $10 billion by 2034, driven by laws like Germany’s supply chain act and the EU forced-labor regulation. The stock still lost 9.38% over the following seven days.

Technically, the shares are deeply oversold. The relative strength index sits at 28.2, and the stochastic oscillator has flashed extreme readings for a week straight. Those signals often precede a bounce. But the broader trend remains firmly bearish, and a short-term recovery doesn’t erase the structural overhang. Annualized volatility over 30 days is running at 124%, a figure that attracts speculators, not patient long-term holders.

The Nasdaq listing adds another layer of urgency. At $0.90, the stock is below the $1 minimum required for continued listing. Persistent noncompliance can trigger delisting proceedings—a heavy blow for any company trying to court institutional investors. The market for compliance technology is expanding, and Diginex’s positioning is plausible, but an aspiring trust-seller can’t afford to look financially fragile itself.

Pelham’s personal $25 million stake signals conviction. Yet that alone may not sway institutions when the company is pursuing a deal worth more than 50 times its own equity while its own shares flirt with exchange minimums. The credibility gap is the central issue: a firm that helps clients manage regulatory risk must itself project regulatory and financial stability.

Three scenarios now vie for the spotlight. The parties could agree to another extension, the remaining conditions could finally be met, or the transaction could collapse. Without a statement from Diginex in the coming week, selling pressure will likely intensify. For the stock to reclaim the $1 threshold and restore confidence, the Resulticks deal needs visible progress—and quickly.